What is the level of liabilities of Allogene Therapeutics this year?
Allogene Therapeutics has a debt balance of 130.6 M USD this year.
In 2024, Allogene Therapeutics's total liabilities amounted to 130.6 M USD, a -13.62% difference from the 151.2 M USD total liabilities in the previous year.
Allogene Therapeutics's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Allogene Therapeutics's financial stability, operational efficiency, and long-term viability.
By comparing Allogene Therapeutics's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.
Allogene Therapeutics's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.
Shifts in Allogene Therapeutics’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.
Allogene Therapeutics has a debt balance of 130.6 M USD this year.
The liabilities of Allogene Therapeutics have increased by -13.62% dropped compared to the previous year.
High liabilities can pose a risk for investors of Allogene Therapeutics, as they can weaken the company's financial position and impair its ability to meet its obligations.
Low liabilities mean that Allogene Therapeutics has a strong financial position and is able to meet its obligations without overburdening its finances.
An increase in liabilities of Allogene Therapeutics can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.
A decrease in the liabilities of Allogene Therapeutics can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.
Some factors that can influence the liabilities of Allogene Therapeutics include investments, acquisitions, operating costs, and sales development.
The liabilities of Allogene Therapeutics are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.
To change its liabilities, Allogene Therapeutics can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.
Over the past 12 months, Allogene Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Allogene Therapeutics is expected to pay a dividend of 0 USD.
The current dividend yield of Allogene Therapeutics is .
Allogene Therapeutics pays a quarterly dividend. This is distributed in the months of .
Allogene Therapeutics paid dividends every year for the past 0 years.
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
Allogene Therapeutics is assigned to the 'Health' sector.
To receive the latest dividend of Allogene Therapeutics from 10/6/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/6/2024.
The last dividend was paid out on 10/6/2024.
In the year 2023, Allogene Therapeutics distributed 0 USD as dividends.
The dividends of Allogene Therapeutics are distributed in USD.
Our stock analysis for Allogene Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Allogene Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.